New HIV vaccine candidates enter human safety testing

NCT ID NCT05471076

First seen Feb 03, 2026 · Last updated May 14, 2026 · Updated 11 times

Summary

This early-stage study tests whether two experimental HIV vaccine priming regimens are safe and can activate special immune cells that make broad antibodies. 52 healthy adults without HIV will receive the vaccines, with some getting a booster shot later. The goal is to see if the vaccines can teach the body to make antibodies that work against many HIV strains.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alabama CRS

    Birmingham, Alabama, 35222, United States

  • Bridge HIV CRS

    San Francisco, California, 94102, United States

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

    Boston, Massachusetts, 02115-6110, United States

  • Columbia P&S CRS

    New York, New York, 10032, United States

  • Seattle Vaccine and Prevention CRS

    Seattle, Washington, 98104, United States

  • The Ponce de Leon Center CRS

    Atlanta, Georgia, 30308-2012, United States

Conditions

Explore the condition pages connected to this study.